25 XP   0   0   10

Xeris Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Xeris Pharmaceuticals Inc together

PenkeI guess you are interested in Xeris Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xeris Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xeris Pharmaceuticals Inc

I send you an email if I find something interesting about Xeris Pharmaceuticals Inc.

Quick analysis of Xeris Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Xeris Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.4%

What is your share worth?

Current worth
$-0.05
Expected worth in 1 year
$-0.19
How sure are you?
37.9%

+ What do you gain per year?

Total Gains per Share
$-0.15
Return On Investment
-8.4%

For what price can you sell your share?

Current Price per Share
$1.74
Expected price per share
$1.39 - $2.34
How sure are you?
50%

1. Valuation of Xeris Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.74

Intrinsic Value Per Share

$1.11 - $1.61

Total Value Per Share

$1.06 - $1.56

2. Growth of Xeris Pharmaceuticals Inc (5 min.)




Is Xeris Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$6.7m$53.5m-$43.3m-425.1%

How much money is Xeris Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15.5m-$26.5m$11m70.8%
Net Profit Margin-39.6%-97.1%--

How much money comes from the company's main activities?

3. Financial Health of Xeris Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#942 / 1016

Most Revenue
#171 / 1016

Most Profit
#639 / 1016

Most Efficient
#531 / 1016

What can you expect buying and holding a share of Xeris Pharmaceuticals Inc? (5 min.)

Welcome investor! Xeris Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Xeris Pharmaceuticals Inc.

What can you expect buying and holding a share of Xeris Pharmaceuticals Inc?

First you should know what it really means to hold a share of Xeris Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Xeris Pharmaceuticals Inc is $1.74. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xeris Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xeris Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.05. Based on the TTM, the Book Value Change Per Share is $-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xeris Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-5.5%-0.12-6.7%-0.17-9.7%-0.18-10.2%-0.15-8.5%
Usd Book Value Change Per Share-0.08-4.4%-0.04-2.1%-0.15-8.3%-0.03-1.7%0.00-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.148.0%0.031.6%0.021.1%
Usd Total Gains Per Share-0.08-4.4%-0.04-2.1%-0.01-0.3%0.00-0.1%0.021.0%
Usd Price Per Share2.35-2.12-1.75-4.16-4.72-
Price to Earnings Ratio-6.16--4.76--2.71--5.99--8.35-
Price-to-Total Gains Ratio-31.00--16.55-70.55--0.33--11.59-
Price to Book Ratio-48.67-13.38-6.91-11.39-10.68-
Price-to-Total Gains Ratio-31.00--16.55-70.55--0.33--11.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.74
Number of shares574
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.04-0.03
Usd Total Gains Per Share-0.040.00
Gains per Quarter (574 shares)-20.87-0.81
Gains per Year (574 shares)-83.46-3.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-83-9364-67-13
20-167-176128-134-16
30-250-259192-202-19
40-334-342256-269-22
50-417-425320-336-25
60-501-508384-403-28
70-584-591448-470-31
80-668-674511-537-34
90-751-757575-605-37
100-835-840639-672-40

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.028.00.03.4%1.028.00.03.4%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%10.016.03.034.5%10.016.03.034.5%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.028.03.4%1.00.028.03.4%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%8.012.00.040.0%11.015.03.037.9%11.015.03.037.9%

Fundamentals of Xeris Pharmaceuticals Inc

About Xeris Pharmaceuticals Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Fundamental data was last updated by Penke on 2024-04-12 22:41:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Xeris Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xeris Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -30.2% means that $-0.30 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xeris Pharmaceuticals Inc:

  • The MRQ is -30.2%. The company is making a huge loss. -2
  • The TTM is -39.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-30.2%TTM-39.6%+9.4%
TTM-39.6%YOY-97.1%+57.6%
TTM-39.6%5Y-1,886.7%+1,847.1%
5Y-1,886.7%10Y-2,027.2%+140.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.2%-199.6%+169.4%
TTM-39.6%-213.0%+173.4%
YOY-97.1%-279.3%+182.2%
5Y-1,886.7%-438.4%-1,448.3%
10Y-2,027.2%-605.5%-1,421.7%
1.1.2. Return on Assets

Shows how efficient Xeris Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • -3.9% Return on Assets means that Xeris Pharmaceuticals Inc generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xeris Pharmaceuticals Inc:

  • The MRQ is -3.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.9%TTM-4.7%+0.8%
TTM-4.7%YOY-8.1%+3.4%
TTM-4.7%5Y-13.9%+9.1%
5Y-13.9%10Y-15.4%+1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.9%-13.5%+9.6%
TTM-4.7%-12.9%+8.2%
YOY-8.1%-11.8%+3.7%
5Y-13.9%-14.1%+0.2%
10Y-15.4%-16.0%+0.6%
1.1.3. Return on Equity

Shows how efficient Xeris Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Xeris Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-129.2%+129.2%
TTM-129.2%YOY-76.1%-53.1%
TTM-129.2%5Y-90.6%-38.6%
5Y-90.6%10Y-68.5%-22.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-129.2%-16.1%-113.1%
YOY-76.1%-15.1%-61.0%
5Y-90.6%-19.9%-70.7%
10Y-68.5%-20.9%-47.6%

1.2. Operating Efficiency of Xeris Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xeris Pharmaceuticals Inc is operating .

  • Measures how much profit Xeris Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -22.2% means the company generated $-0.22  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xeris Pharmaceuticals Inc:

  • The MRQ is -22.2%. The company is operating very inefficient. -2
  • The TTM is -30.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-22.2%TTM-30.0%+7.8%
TTM-30.0%YOY-72.1%+42.1%
TTM-30.0%5Y-1,781.2%+1,751.2%
5Y-1,781.2%10Y-1,942.3%+161.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.2%-295.1%+272.9%
TTM-30.0%-225.8%+195.8%
YOY-72.1%-288.4%+216.3%
5Y-1,781.2%-477.4%-1,303.8%
10Y-1,942.3%-625.6%-1,316.7%
1.2.2. Operating Ratio

Measures how efficient Xeris Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are $1.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 1.222. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.272. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.222TTM1.272-0.050
TTM1.272YOY1.721-0.449
TTM1.2725Y19.204-17.932
5Y19.20410Y25.465-6.261
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2223.090-1.868
TTM1.2723.264-1.992
YOY1.7213.783-2.062
5Y19.2045.679+13.525
10Y25.4657.894+17.571

1.3. Liquidity of Xeris Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xeris Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.64 means the company has $1.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 1.642. The company is able to pay all its short-term debts. +1
  • The TTM is 1.861. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.642TTM1.861-0.220
TTM1.861YOY2.289-0.428
TTM1.8615Y4.068-2.207
5Y4.06810Y5.279-1.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6423.914-2.272
TTM1.8614.220-2.359
YOY2.2895.388-3.099
5Y4.0686.045-1.977
10Y5.2796.406-1.127
1.3.2. Quick Ratio

Measures if Xeris Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.23 means the company can pay off $1.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 1.225. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.663. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.225TTM1.663-0.438
TTM1.663YOY2.264-0.601
TTM1.6635Y5.378-3.715
5Y5.37810Y6.154-0.775
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2253.572-2.347
TTM1.6633.998-2.335
YOY2.2645.390-3.126
5Y5.3785.969-0.591
10Y6.1546.287-0.133

1.4. Solvency of Xeris Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xeris Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xeris Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.02 means that Xeris Pharmaceuticals Inc assets are financed with 102.0% credit (debt) and the remaining percentage (100% - 102.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 1.020. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.968. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.020TTM0.968+0.052
TTM0.968YOY0.837+0.131
TTM0.9685Y0.808+0.160
5Y0.80810Y0.693+0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0200.336+0.684
TTM0.9680.334+0.634
YOY0.8370.269+0.568
5Y0.8080.366+0.442
10Y0.6930.390+0.303
1.4.2. Debt to Equity Ratio

Measures if Xeris Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xeris Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM29.151-29.151
TTM29.151YOY9.652+19.500
TTM29.1515Y10.017+19.134
5Y10.01710Y6.992+3.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM29.1510.396+28.755
YOY9.6520.335+9.317
5Y10.0170.434+9.583
10Y6.9920.465+6.527

2. Market Valuation of Xeris Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xeris Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Xeris Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -6.16 means the investor is paying $-6.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xeris Pharmaceuticals Inc:

  • The EOD is -4.563. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.163. Based on the earnings, the company is expensive. -2
  • The TTM is -4.760. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.563MRQ-6.163+1.600
MRQ-6.163TTM-4.760-1.402
TTM-4.760YOY-2.713-2.047
TTM-4.7605Y-5.989+1.229
5Y-5.98910Y-8.350+2.360
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.563-2.259-2.304
MRQ-6.163-2.569-3.594
TTM-4.760-2.664-2.096
YOY-2.713-4.120+1.407
5Y-5.989-6.258+0.269
10Y-8.350-6.171-2.179
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xeris Pharmaceuticals Inc:

  • The EOD is 9.928. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 13.409. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 0.214. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD9.928MRQ13.409-3.481
MRQ13.409TTM0.214+13.195
TTM0.214YOY-2.396+2.610
TTM0.2145Y-5.843+6.057
5Y-5.84310Y-8.011+2.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.928-2.924+12.852
MRQ13.409-3.246+16.655
TTM0.214-3.488+3.702
YOY-2.396-5.620+3.224
5Y-5.843-8.315+2.472
10Y-8.011-8.826+0.815
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xeris Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -48.67 means the investor is paying $-48.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Xeris Pharmaceuticals Inc:

  • The EOD is -36.035. Based on the equity, the company is expensive. -2
  • The MRQ is -48.668. Based on the equity, the company is expensive. -2
  • The TTM is 13.380. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-36.035MRQ-48.668+12.633
MRQ-48.668TTM13.380-62.048
TTM13.380YOY6.910+6.470
TTM13.3805Y11.392+1.987
5Y11.39210Y10.685+0.708
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-36.0351.851-37.886
MRQ-48.6682.090-50.758
TTM13.3802.095+11.285
YOY6.9102.844+4.066
5Y11.3923.466+7.926
10Y10.6853.815+6.870
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Xeris Pharmaceuticals Inc.

3.1. Institutions holding Xeris Pharmaceuticals Inc

Institutions are holding 44.82% of the shares of Xeris Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc7.12790.0006100113916371496.7968
2023-12-31Vanguard Group Inc5.04530.00047086345601810.8565
2023-12-31Stonepine Capital Management Llc4.2276.03385937000216280.3656
2023-12-31Caxton Corp4.016971.5735564192000
2023-12-31MPM Oncology Impact Management LP2.73922.11523847232-140735-3.529
2023-12-31Rosalind Advisors, Inc.2.5236.8585354368535436850
2023-12-31Geode Capital Management, LLC2.05910.000728920771187844.2831
2023-12-31State Street Corporation1.93950.000327241261540045.9921
2023-12-31Millennium Management LLC1.10210.00161547955-726189-31.9324
2023-12-31Renaissance Technologies Corp0.98370.005138164035960035.1845
2023-12-31Morgan Stanley - Brokerage Accounts0.86960.0003122135858312691.3658
2023-12-31Northern Trust Corp0.82970.00051165363201461.7591
2023-09-30Redmile Group, LLC0.74510.0926104658700
2023-09-30D. E. Shaw & Co LP0.62330.001787541014935920.5714
2023-09-30Point72 Asset Management, L.P.0.46630.00366550006550000
2023-12-31Invenomic Capital Management, LP0.40480.0615686195686190
2023-12-31Tudor Investment Corp Et AL0.3940.0105553411-88087-13.7315
2023-12-31Ameriprise Financial Inc0.37030.0004520121-67817-11.5347
2023-12-31Goldman Sachs Group Inc0.36840.0001517378384538289.4746
2023-12-31Nuveen Asset Management, LLC0.30260.0003424972-287725-40.3713
Total 37.137886.760652161590+5945266+11.4%

3.2. Funds holding Xeris Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.92410.0008410699100
2024-03-28iShares Russell 2000 ETF2.33120.0111327430315780.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.43110.00612010089170680.8564
2024-01-31Fidelity Small Cap Index0.95880.01341346641271492.0575
2024-03-28iShares Russell 2000 Growth ETF0.82480.0221158390-1347-0.1161
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.57520.00680784067000.8363
2024-02-29Fidelity Extended Market Index0.57210.0064803594323314.192
2024-01-31CREF Stock R10.46050.00146467806467800
2024-01-31Invenomic Institutional0.44870.10826301826301820
2023-11-30MEDICAL BioHealth EUR Acc0.41810.1699587239-940059-61.5505
2024-02-29Vanguard Russell 2000 ETF0.34690.0157487232379938.4572
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.340.010847753900
2024-03-28SPDR® S&P Pharmaceuticals ETF0.29550.41741502700
2023-12-31NT R2000 Growth Index Fund - NL0.28060.02539408629530.755
2023-12-31Lazard Rathmore Alternative EA Acc USD0.28060.05353940548619227.997
2023-12-31NT R2000 Index Fund - NL0.26910.012337797134750.9279
2023-09-30BlackRock Extended Mkt Composite0.26820.0042376723-60859-13.908
2024-03-31BlackRock Extended Equity Market K0.24230.0052340339151074.645
2024-02-29Schwab Small Cap Index0.21750.015930545319110.6296
2023-12-31NT R2000 Growth Index Fund - L0.21330.0254299565164115.7958
Total 13.69860.930319240038+523565+2.7%

3.3. Insider Transactions

Insiders are holding 3.872% of the shares of Xeris Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-14John P SchmidBUY45002.16
2023-11-27Jeffrey W ShermanBUY54001.87
2023-11-17John Patrick Shannon JrBUY307691.64
2023-11-16John P SchmidBUY65001.51
2023-08-09Paul R EdickBUY100002.38

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Xeris Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.076-0.036-52%-0.145+92%-0.029-61%-0.002-98%
Book Value Per Share---0.0480.073-167%0.381-113%0.267-118%0.277-117%
Current Ratio--1.6421.861-12%2.289-28%4.068-60%5.279-69%
Debt To Asset Ratio--1.0200.968+5%0.837+22%0.808+26%0.693+47%
Debt To Equity Ratio---29.151-100%9.652-100%10.017-100%6.992-100%
Dividend Per Share----0%0.139-100%0.028-100%0.019-100%
Eps---0.095-0.116+22%-0.168+77%-0.178+86%-0.147+54%
Free Cash Flow Per Share--0.044-0.090+305%-0.197+550%-0.158+461%-0.133+405%
Free Cash Flow To Equity Per Share--0.043-0.091+308%-0.058+234%-0.047+209%-0.016+137%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.610--------
Intrinsic Value_10Y_min--1.113--------
Intrinsic Value_1Y_max---0.501--------
Intrinsic Value_1Y_min---0.492--------
Intrinsic Value_3Y_max---1.000--------
Intrinsic Value_3Y_min---0.965--------
Intrinsic Value_5Y_max---0.891--------
Intrinsic Value_5Y_min---0.871--------
Market Cap244388206.080-35%330064531.200297058078.080+11%245441603.520+34%584495126.208-44%662502233.644-50%
Net Profit Margin---0.302-0.396+31%-0.971+222%-18.867+6155%-20.272+6620%
Operating Margin---0.222-0.300+35%-0.721+225%-17.812+7935%-19.423+8661%
Operating Ratio--1.2221.272-4%1.721-29%19.204-94%25.465-95%
Pb Ratio-36.035+26%-48.66813.380-464%6.910-804%11.392-527%10.685-555%
Pe Ratio-4.563+26%-6.163-4.760-23%-2.713-56%-5.989-3%-8.350+35%
Price Per Share1.740-35%2.3502.115+11%1.748+34%4.162-44%4.717-50%
Price To Free Cash Flow Ratio9.928-35%13.4090.214+6169%-2.396+118%-5.843+144%-8.011+160%
Price To Total Gains Ratio-22.954+26%-31.001-16.550-47%70.545-144%-0.328-99%-11.587-63%
Quick Ratio--1.2251.663-26%2.264-46%5.378-77%6.154-80%
Return On Assets---0.039-0.047+20%-0.081+107%-0.139+253%-0.154+291%
Return On Equity----1.2920%-0.7610%-0.9060%-0.6850%
Total Gains Per Share---0.076-0.036-52%-0.006-92%-0.001-98%0.018-532%
Usd Book Value---6782000.00010193000.000-167%53521750.000-113%37567950.000-118%38968896.552-117%
Usd Book Value Change Per Share---0.076-0.036-52%-0.145+92%-0.029-61%-0.002-98%
Usd Book Value Per Share---0.0480.073-167%0.381-113%0.267-118%0.277-117%
Usd Dividend Per Share----0%0.139-100%0.028-100%0.019-100%
Usd Eps---0.095-0.116+22%-0.168+77%-0.178+86%-0.147+54%
Usd Free Cash Flow--6154000.000-12617750.000+305%-27722000.000+550%-22219350.000+461%-18746931.034+405%
Usd Free Cash Flow Per Share--0.044-0.090+305%-0.197+550%-0.158+461%-0.133+405%
Usd Free Cash Flow To Equity Per Share--0.043-0.091+308%-0.058+234%-0.047+209%-0.016+137%
Usd Market Cap244388206.080-35%330064531.200297058078.080+11%245441603.520+34%584495126.208-44%662502233.644-50%
Usd Price Per Share1.740-35%2.3502.115+11%1.748+34%4.162-44%4.717-50%
Usd Profit---13390000.000-15563750.000+16%-26587000.000+99%-25402400.000+90%-20961758.621+57%
Usd Revenue--44390000.00040978500.000+8%29645750.000+50%17751250.000+150%12417965.517+257%
Usd Total Gains Per Share---0.076-0.036-52%-0.006-92%-0.001-98%0.018-532%
 EOD+3 -5MRQTTM+19 -13YOY+21 -135Y+17 -1710Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Xeris Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.563
Price to Book Ratio (EOD)Between0-1-36.035
Net Profit Margin (MRQ)Greater than0-0.302
Operating Margin (MRQ)Greater than0-0.222
Quick Ratio (MRQ)Greater than11.225
Current Ratio (MRQ)Greater than11.642
Debt to Asset Ratio (MRQ)Less than11.020
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.039
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Xeris Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.625
Ma 20Greater thanMa 501.990
Ma 50Greater thanMa 1002.432
Ma 100Greater thanMa 2002.356
OpenGreater thanClose1.760
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Stockholder Equity 13,64116,40730,048-16,40713,641-9,7763,865-10,647-6,782



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets340,798
Total Liabilities347,580
Total Stockholder Equity-6,782
 As reported
Total Liabilities 347,580
Total Stockholder Equity+ -6,782
Total Assets = 340,798

Assets

Total Assets340,798
Total Current Assets156,264
Long-term Assets184,534
Total Current Assets
Cash And Cash Equivalents 67,449
Short-term Investments 5,002
Net Receivables 39,197
Inventory 38,838
Other Current Assets 5,778
Total Current Assets  (as reported)156,264
Total Current Assets  (calculated)156,264
+/-0
Long-term Assets
Property Plant Equipment 29,175
Goodwill 22,859
Intangible Assets 109,764
Long-term Assets Other 315
Long-term Assets  (as reported)184,534
Long-term Assets  (calculated)162,113
+/- 22,421

Liabilities & Shareholders' Equity

Total Current Liabilities95,193
Long-term Liabilities252,387
Total Stockholder Equity-6,782
Total Current Liabilities
Short-term Debt 3,495
Accounts payable 11,565
Other Current Liabilities 80,133
Total Current Liabilities  (as reported)95,193
Total Current Liabilities  (calculated)95,193
+/-0
Long-term Liabilities
Long term Debt 190,932
Capital Lease Obligations 38,259
Long-term Liabilities Other 6,227
Long-term Liabilities  (as reported)252,387
Long-term Liabilities  (calculated)235,418
+/- 16,969
Total Stockholder Equity
Common Stock14
Retained Earnings -617,025
Accumulated Other Comprehensive Income -25
Other Stockholders Equity 610,254
Total Stockholder Equity (as reported)-6,782
Total Stockholder Equity (calculated)-6,782
+/-0
Other
Capital Stock14
Cash and Short Term Investments 72,451
Common Stock Shares Outstanding 138,125
Liabilities and Stockholders Equity 340,798
Net Debt 161,742
Net Invested Capital 184,150
Net Working Capital 61,071
Property Plant and Equipment Gross 35,211
Short Long Term Debt Total 229,191



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
33,533
0
0
0
44,998
61,564
138,256
137,591
120,028
160,970
133,894
128,100
108,987
116,462
165,810
170,459
159,151
167,637
151,496
131,260
304,361
337,623
318,616
321,360
328,778
321,360
328,778
327,784
340,798
340,798327,784328,778321,360328,778321,360318,616337,623304,361131,260151,496167,637159,151170,459165,810116,462108,987128,100133,894160,970120,028137,591138,25661,56444,99800033,533
   > Total Current Assets 
33,174
0
0
0
44,053
59,835
137,032
135,670
117,899
153,445
126,149
105,976
87,483
105,520
156,363
163,226
152,212
160,626
144,588
124,367
142,596
177,550
161,206
165,513
155,741
165,513
155,741
158,051
156,264
156,264158,051155,741165,513155,741165,513161,206177,550142,596124,367144,588160,626152,212163,226156,363105,52087,483105,976126,149153,445117,899135,670137,03259,83544,05300033,174
       Cash And Cash Equivalents 
32,269
0
0
0
42,045
58,110
134,528
75,745
45,716
61,984
66,669
56,160
19,519
39,244
102,465
37,886
37,598
66,604
63,599
59,492
67,271
103,771
95,340
50,984
46,170
50,984
46,170
46,143
67,449
67,44946,14346,17050,98446,17050,98495,340103,77167,27159,49263,59966,60437,59837,886102,46539,24419,51956,16066,66961,98445,71675,745134,52858,11042,04500032,269
       Short-term Investments 
0
0
0
0
0
0
0
55,296
66,917
85,687
57,841
46,311
56,030
57,698
41,530
103,857
96,190
69,290
52,381
33,491
35,162
28,377
16,213
44,118
34,498
44,118
34,498
19,832
5,002
5,00219,83234,49844,11834,49844,11816,21328,37735,16233,49152,38169,29096,190103,85741,53057,69856,03046,31157,84185,68766,91755,2960000000
       Net Receivables 
101
0
0
0
1,199
287
1,065
1,731
2,869
3,628
826
874
5,639
3,258
3,872
12,190
6,875
8,938
12,295
13,561
17,456
23,383
25,756
30,860
30,225
30,860
30,225
45,966
39,197
39,19745,96630,22530,86030,22530,86025,75623,38317,45613,56112,2958,9386,87512,1903,8723,2585,6398748263,6282,8691,7311,0652871,199000101
       Other Current Assets 
804
0
0
0
809
1,438
1,439
2,898
2,397
2,146
813
2,631
4,119
3,154
3,672
3,660
3,196
3,298
4,014
3,582
4,589
5,147
6,010
10,512
8,310
10,512
8,310
7,967
5,778
5,7787,9678,31010,5128,31010,5126,0105,1474,5893,5824,0143,2983,1963,6603,6723,1544,1192,6318132,1462,3972,8981,4391,438809000804
   > Long-term Assets 
0
0
0
0
945
1,729
1,224
1,921
2,129
7,525
7,745
22,124
21,504
10,942
9,447
7,233
6,939
7,011
6,908
6,893
161,765
160,073
157,410
155,847
173,037
155,847
173,037
169,733
184,534
184,534169,733173,037155,847173,037155,847157,410160,073161,7656,8936,9087,0116,9397,2339,44710,94221,50422,1247,7457,5252,1291,9211,2241,7299450000
       Property Plant Equipment 
312
0
0
0
788
1,058
1,136
1,826
2,034
7,430
7,677
7,952
7,853
7,593
7,387
6,928
6,707
6,799
6,697
6,682
6,627
6,291
6,170
10,363
30,184
10,363
30,184
29,592
29,175
29,17529,59230,18410,36330,18410,3636,1706,2916,6276,6826,6976,7996,7076,9287,3877,5937,8537,9527,6777,4302,0341,8261,1361,058788000312
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,859
22,859
22,859
22,859
22,859
22,859
22,859
22,859
22,859
22,85922,85922,85922,85922,85922,85922,85922,85922,85900000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
13,913
13,231
2,992
1,790
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,7902,99213,23113,91300000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131,450
128,739
126,029
117,896
115,186
117,896
115,186
112,475
109,764
109,764112,475115,186117,896115,186117,896126,029128,739131,45000000000000000000000
       Long-term Assets Other 
0
0
0
0
157
671
88
95
95
95
68
259
420
357
270
305
232
212
211
211
829
2,184
2,352
4,729
345
4,729
4,808
4,807
315
3154,8074,8084,7293454,7292,3522,18482921121121223230527035742025968959595886711570000
> Total Liabilities 
2,569
0
0
0
102,828
28,714
28,919
42,471
44,622
53,870
59,103
84,444
94,551
89,393
141,429
156,198
125,390
123,250
131,608
133,721
209,130
241,168
244,673
291,312
315,137
291,312
315,137
323,919
347,580
347,580323,919315,137291,312315,137291,312244,673241,168209,130133,721131,608123,250125,390156,198141,42989,39394,55184,44459,10353,87044,62242,47128,91928,714102,8280002,569
   > Total Current Liabilities 
2,527
0
0
0
4,860
9,191
9,189
8,208
10,172
13,406
21,008
17,792
27,338
21,880
22,787
27,175
28,207
27,424
35,464
37,285
79,040
66,492
64,545
81,423
79,678
81,423
79,678
87,039
95,193
95,19387,03979,67881,42379,67881,42364,54566,49279,04037,28535,46427,42428,20727,17522,78721,88027,33817,79221,00813,40610,1728,2089,1899,1914,8600002,527
       Short-term Debt 
0
0
0
0
2,557
7,559
7,542
6,260
8,214
11,482
3,000
15,706
0
0
0
0
0
0
0
0
0
341
0
1,448
1,935
1,448
1,935
2,366
3,495
3,4952,3661,9351,4481,9351,448034100000000015,7063,00011,4828,2146,2607,5427,5592,5570000
       Short Long Term Debt 
0
0
0
0
0
18,051
18,167
0
0
0
3,000
0
0
0
0
0
0
0
0
0
0
341
0
0
0
0
0
0
0
000000034100000000003,00000018,16718,05100000
       Accounts payable 
1,315
0
0
0
1,976
847
556
622
866
1,408
1,840
1,678
5,603
3,840
4,440
4,694
3,117
4,768
5,185
4,290
8,924
11,091
6,631
11,983
11,621
11,983
11,621
12,078
11,565
11,56512,07811,62111,98311,62111,9836,63111,0918,9244,2905,1854,7683,1174,6944,4403,8405,6031,6781,8401,4088666225568471,9760001,315
       Other Current Liabilities 
1,212
0
0
0
93
501
807
1,042
860
295
16,012
302
21,735
18,040
18,347
22,481
25,090
22,656
30,279
32,995
70,116
55,060
57,914
67,992
18,355
17,715
18,355
18,640
80,133
80,13318,64018,35517,71518,35567,99257,91455,06070,11632,99530,27922,65625,09022,48118,34718,04021,73530216,0122958601,042807501930001,212
   > Long-term Liabilities 
0
0
0
0
97,968
19,523
19,730
34,263
34,450
40,464
38,095
66,652
67,213
67,513
118,642
129,023
97,183
95,826
96,144
96,436
130,090
174,676
180,128
209,889
235,459
209,889
235,459
236,880
252,387
252,387236,880235,459209,889235,459209,889180,128174,676130,09096,43696,14495,82697,183129,023118,64267,51367,21366,65238,09540,46434,45034,26319,73019,52397,9680000
       Long term Debt Total 
0
0
0
0
0
0
18,167
31,642
31,890
32,141
29,403
58,124
58,305
58,485
109,476
119,391
87,021
87,272
87,478
0
0
0
0
0
0
0
0
0
0
000000000087,47887,27287,021119,391109,47658,48558,30558,12429,40332,14131,89031,64218,167000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-2,557
-7,559
-7,542
-6,260
-8,214
-11,482
-3,000
-15,706
0
0
0
0
0
0
0
0
0
-341
0
-1,448
9,047
9,346
34,871
35,154
34,764
34,76435,15434,8719,3469,047-1,4480-341000000000-15,706-3,000-11,482-8,214-6,260-7,542-7,559-2,5570000
       Long-term Liabilities Other 
0
0
0
0
0
0
1,563
2,621
0
8,323
8,692
8,528
8,908
9,028
9,166
9,632
3,533
1,862
1,897
1,897
30,198
25,561
31,066
30,411
25,719
9,402
9,563
8,799
6,227
6,2278,7999,5639,40225,71930,41131,06625,56130,1981,8971,8971,8623,5339,6329,1669,0288,9088,5288,6928,32302,6211,563000000
       Deferred Long Term Liability 
0
0
0
0
0
582
0
0
0
0
0
0
400
0
0
0
6,629
6,692
6,769
0
0
0
0
0
0
0
0
0
0
00000000006,7696,6926,62900040000000058200000
> Total Stockholder Equity
30,964
-31,934
0
0
-57,830
32,850
109,337
95,120
75,406
107,100
74,791
43,656
14,436
27,069
24,381
14,261
33,761
44,387
19,888
-2,461
95,231
96,455
73,943
30,048
13,641
30,048
13,641
3,865
-6,782
-6,7823,86513,64130,04813,64130,04873,94396,45595,231-2,46119,88844,38733,76114,26124,38127,06914,43643,65674,791107,10075,40695,120109,33732,850-57,83000-31,93430,964
   Common Stock
1
0
0
0
1
1
2
2
2
3
3
3
3
4
5
5
6
7
7
7
13
14
14
14
14
14
14
14
14
14141414141414141377765543333222110001
   Retained Earnings Total Equity0000000000-383,311-355,796-337,400-315,528-299,528-275,429-246,200-213,1630-145,9420-100,200-85,478000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-440
0
0
-58
-52
-1
68
45
43
60
164
56
6
-10
-20
-26
-31
-66
-52
-29
-78
-29
-78
-50
-25
-25-50-78-29-78-29-52-66-31-26-20-1065616460434568-1-52-5800-4400000
   Capital Surplus 
0
0
0
0
0
0
194,813
195,422
196,121
253,040
255,047
256,771
260,635
302,434
323,740
329,803
371,134
400,186
403,212
0
0
0
0
0
0
0
0
0
0
0000000000403,212400,186371,134329,803323,740302,434260,635256,771255,047253,040196,121195,422194,813000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
3,194
105,341
194,813
195,422
196,121
253,040
255,047
256,771
260,635
302,434
323,740
329,803
371,134
400,186
403,212
406,878
555,359
590,331
593,990
601,667
13,641
601,667
605,151
3,865
610,254
610,2543,865605,151601,66713,641601,667593,990590,331555,359406,878403,212400,186371,134329,803323,740302,434260,635256,771255,047253,040196,121195,422194,813105,3413,1940000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue163,914
Cost of Revenue-39,488
Gross Profit124,426124,426
 
Operating Income (+$)
Gross Profit124,426
Operating Expense-168,436
Operating Income-44,010-44,010
 
Operating Expense (+$)
Research Development22,341
Selling General Administrative146,095
Selling And Marketing Expenses0
Operating Expense168,436168,436
 
Net Interest Income (+$)
Interest Income4,751
Interest Expense-26,609
Other Finance Cost-0
Net Interest Income-21,858
 
Pretax Income (+$)
Operating Income-44,010
Net Interest Income-21,858
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-63,504-24,516
EBIT - interestExpense = -70,619
-63,504
-35,646
Interest Expense26,609
Earnings Before Interest and Taxes (EBIT)-44,010-36,895
Earnings Before Interest and Taxes (EBITDA)-30,850
 
After tax Income (+$)
Income Before Tax-63,504
Tax Provision--1,249
Net Income From Continuing Ops-62,255-62,255
Net Income-62,255
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses207,924
Total Other Income/Expenses Net-19,49421,858
 

Technical Analysis of Xeris Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xeris Pharmaceuticals Inc. The general trend of Xeris Pharmaceuticals Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xeris Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xeris Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2 < 2.28 < 2.34.

The bearish price targets are: 1.56 > 1.46 > 1.39.

Tweet this
Xeris Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xeris Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xeris Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xeris Pharmaceuticals Inc. The current macd is -0.16180222.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Xeris Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xeris Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xeris Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Xeris Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartXeris Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xeris Pharmaceuticals Inc. The current adx is 30.80.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xeris Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Xeris Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xeris Pharmaceuticals Inc. The current sar is 2.00375441.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Xeris Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xeris Pharmaceuticals Inc. The current rsi is 25.63. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Xeris Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartXeris Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xeris Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xeris Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xeris Pharmaceuticals Inc Daily Stochastic Oscillator ChartXeris Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xeris Pharmaceuticals Inc. The current cci is -158.67786216.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Xeris Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartXeris Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xeris Pharmaceuticals Inc. The current cmo is -61.63557101.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xeris Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartXeris Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xeris Pharmaceuticals Inc. The current willr is -88.63636364.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Xeris Pharmaceuticals Inc Daily Williams %R ChartXeris Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xeris Pharmaceuticals Inc.

Xeris Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xeris Pharmaceuticals Inc. The current atr is 0.11421002.

Xeris Pharmaceuticals Inc Daily Average True Range (ATR) ChartXeris Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xeris Pharmaceuticals Inc. The current obv is -50,426,144.

Xeris Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartXeris Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xeris Pharmaceuticals Inc. The current mfi is 12.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Xeris Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartXeris Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xeris Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Xeris Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xeris Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.625
Ma 20Greater thanMa 501.990
Ma 50Greater thanMa 1002.432
Ma 100Greater thanMa 2002.356
OpenGreater thanClose1.760
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xeris Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Xeris Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xeris Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xeris Pharmaceuticals Inc

I send you an email if I find something interesting about Xeris Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Xeris Pharmaceuticals Inc.

Receive notifications about Xeris Pharmaceuticals Inc in your mailbox!